Last updated on February 2020

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Brief description of study

This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

Clinical Study Identifier: NCT03570892

Find a site near you

Start Over

Novartis Investigative Site

Lille Cedex, France
  Connect »